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G protein coupled receptor
A B S T R A C T
Serotonin (5-HT) is an important regulator of numerous aspects of flatworm biology, ranging from neuromus-
cular function to sexual maturation and egg laying. In the parasitic blood fluke Schistosoma mansoni, 5-HT targets
several G-protein coupled receptors (GPCRs), one of which has been demonstrated to couple to cAMP and
regulate parasite movement. This receptor, Sm.5HTRL, has been successfully co-expressed in mammalian cells
alongside a luminescent cAMP-biosensor, enabling pharmacological profiling for candidate anti-schistosomal
drugs. Here, we have utilized this assay to perform structure-activity investigations of 143 compounds con-
taining previously identified alkaloid natural product pharmacophores (tryptamines, aporphines and proto-
berberines) shown to regulate Sm.5HTRL. These experiments mapped regions of the tryptamine pharmacophore
amenable and intolerant to substitution, highlighting differences relative to orthologous mammalian 5-HT re-
ceptors. Potent Sm.5HTRL antagonists were identified, and the efficacy of these compounds were evaluated
against live adult parasites cultured ex vivo. Such structure-activity profiling, characterizing the effect of various
modifications to these core ring systems on Sm.5HTRL responses, provides greater understanding of pharma-
cophores selective for this target to aid future drug development efforts.
1. Introduction
Flatworm G-protein coupled receptors (GPCRs) are promising an-
thelmintic drug targets, given their role regulating movement, sexual
maturation and egg laying (Patocka et al., 2014; Saberi et al., 2016;
Chan et al., 2018; Hahnel et al., 2018). Over 200 million people
worldwide are infected with the parasitic Schistosoma flatworms that
cause the disease schistosomiasis (Hotez and Fenwick, 2009). This
disease is largely treated by just one broad spectrum anti-schistosomal
drug, praziquantel (PZQ) (Andrews et al., 1983). PZQ has been en-
ormously beneficial in mitigating morbidity due to schistosomiasis and
moving towards control of this disease, but drawbacks include PZQ's
ineffectiveness against immature parasites (Sabah et al., 1986), fre-
quent side effects (Coulibaly et al., 2017), and cure rates that are rarely
100% effective (Olliaro et al., 2011; Coulibaly et al., 2017). Reliance on
a single compound also raises the concern of emerging drug resistance.
Therefore, there is a need for new anti-schistosomal drugs, either to
supplement PZQ or to serve as an alternative in the event of treatment
failure.
In the past several years, several studies have prioritized flatworm
GPCRs as targets for drug development. RNAi and pharmacological
approaches have identified serotonin (5-HT) GPCRs that control flat-
worm movement (Patocka et al., 2014; Chan et al., 2015), and GPCRs
have also been implicated in flatworm sexual maturation and egg laying
(Lu et al., 2016; Saberi et al., 2016; Wang et al., 2017; Chan et al.,
2018). Additionally, while the parasite target(s) of PZQ remains un-
defined, our recent work has shown that the active R-PZQ enantiomer
acts as a GPCR ligand, engaging human serotonergic GPCRs that reg-
ulate mesenteric vessel tone (Chan et al., 2017). Precedent for en-
gagement of GPCRs by PZQ should prioritize development of scalable
functional assays to study flatworm GPCRs in more detail. One such
approach centers upon co-expression of Gαs/Gαi coupled GPCRs with
GloSensor, a modified luciferase reporter which detects changes in
cellular cAMP levels. This assay provides a high sensitivity and real-
time readout of GPCR activity that can be scaled to miniaturized
format. Previously, we optimized this methodology to enable pharma-
cological profiling of a schistosome serotonergic GPCR (Sm.5HTRL) that
controls worm movement (Patocka et al., 2014; Chan et al., 2016c).
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This approach implicated several classes of natural product heterocyclic
alkaloid scaffolds as regulators of Sm.5HTRL activity (Chan et al.,
2016b, 2016c, 2018). As natural products have a proven track record as
leads for drug development (Newman and Cragg, 2012), we subse-
quently performed a more extensive analysis of structure-activity re-
lationships for ergot alkaloids (Chan et al., 2018), and here in this
study, tryptamine, aporphine and protoberberine scaffolds at this
parasite GPCR. As these compounds are known regulators of mamma-
lian 5-HT receptors (Cabedo et al., 2009; Harding, 2016), the goal is to
understand pharmacophore features that determine selectivity and
potency for Sm.5HTRL to identify effective small molecule tools useful
for probing schistosome biology as well as potential leads for anthel-
mintic development.
2. Materials and methods
Chemicals. A complete list of chemical structures and vendors for the
compounds used in this work is provided in Supplemental Table 1.
Compounds were selected from libraries sourced from the National
Cancer Institute (NCI Natural Products Set IV) as well as commercial
vendors (TimTec Natural Product Library and NDL-3000 Natural De-
rivatives Library). Individual compounds were also sourced from var-
ious vendors (Tocris, Sigma Aldrich, Santa Cruz, Pharmeks and Abcam,
see Supplemental Table 1 for catalog numbers) identified through
searches of the ZINC and PubChem databases. Finally, several apor-
phine compounds were kindly provided by Wayne Harding (CUNY).
The synthesis and activity profile of these compounds against mam-
malian bioaminergic receptors has been reported elsewhere
(Chaudhary et al., 2009, 2011; Kapadia and Harding, 2015).
Cell culture. HEK-293 cells (ATCC CRL-1573, authenticated by STR
profiling) were cultured in growth media consisting of DMEM supple-
mented with GlutaMAX (Gibco cat # 10566016), 10% heat inactivated
fetal bovine serum and penicillin-streptomycin (100 units/mL,
ThermoFisher). GPCR functional assays were performed as described in
(Chan et al., 2018). The coding sequence for Sm.5HTRL (GenBank ac-
cession number KX150867) was codon optimized for mammalian ex-
pression and sub-cloned into pcDNA3.1 (−) between NotI and EcoRI.
Stable cell lines for the GloSensor-22F cAMP Plasmid (Promega) and
schistosome 5HTRs were selected with hygromycin (200 μg/mL) and
G418 (400 μg/mL). These lines were then cultured in DMEM supple-
mented with GlutaMAX, Pen-Strep, and 10% dialyzed FBS.
cAMP luminescence assays. Stable cell lines expressing the GloSensor-
22F construct or both GloSensor-22F and Sm.5HTRL were cultured in T-
75 flasks. The day prior to performing assays, cells were trypsinized
(TrypLE Express, Gibco) and plated in solid white 96 well plates (Costar
cat # 3917) at a density of 2.5x104 cells/well. One day later media was
removed and replaced with assay buffer (HBSS buffered with HEPES
(20 mM, pH 7.4) + BSA (0.1% w/v) and D-luciferin sodium salt (1 mg/
mL, Gold Biotechnology). Plates were equilibrated at room temperature
for 1 h, the phosphodiesterase inhibitor 3-Isobutyl-1-methylxanthine
(IBMX 200 μM, Sigma Aldrich) was added, and plates were equilibrated
for a further 30 min prior to test compound addition. Test compounds
were added and luminescence was read for 45 min on a GloMax®-Multi
Detection System plate reader (Promega) to identify agonist responses.
Plates were removed, and a maximal concentration of serotonin
(500 nM) was added to each well. Plates were immediately returned to
the plate reader and read for a further 45min to identify compounds
with antagonist activity.
Adult schistosome mobility assays. Female Swiss Webster mice in-
fected with S. mansoni cercariae (NMRI strain) were sacrificed 49 days
post infection by CO2 euthanasia. Adult schistosomes were recovered
by dissection of the mesenteric vasculature. Harvested schistosomes
were washed in RPMI 1640 supplemented with HEPES (25mM), 5%
heat inactivated FBS (Gibco) and penicillin-streptomycin (100 units/
mL). Worms were cultured overnight (37 °C/5% CO2) in vented
100× 25mm petri dishes (ThermoFisher cat # 4031) containing 50mL
of media. Movement assays were performed the next day. Male worms
were transferred to a six well dish (4–5 individual worms per well)
containing 3mL media. For agonist assays, worms were incubated for
5min in various concentrations of drug prior to acquiring videos of
worm movement. For antagonist assays, worms were incubated for 1 h
in test compound, and then a maximal concentration of serotonin
(200 μM) was added before videos were acquired. Imaging was per-
formed using a Zeiss Discovery v20 stereomicroscope and a QiCAM 12-
bit cooled color CCD camera controlled by Metamorph imaging soft-
ware (version 7.8.1.0). Recordings (1 min) were acquired at 4 frames
per second, saved as an image stack, and movement analyzed using
ImageJ software as described in (Chan et al., 2016c). Data represents
mean ± standard error for ≥3 independent experiments. Animal work
was carried out with the oversight and approval of the Laboratory
Animal Resources facility at the Medical College of Wisconsin. All an-
imal experiments followed ethical regulations approved by the Medical
College of Wisconsin IACUC committee.
3. Results
The schistosome serotonin (5-HT) receptor Sm.5HTRL was ex-
pressed in mammalian HEK-293 cells alongside the GloSensor 22-F
cAMP luminescent reporter (Chan et al., 2016a, 2016c). Addition of 5-
HT caused a rapid increase in cAMP-dependent luminescence in cells
Fig. 1. Functional expression of Sm.5HTRL. (A) Kinetics and (B) dose-response curves for 5-HT evoked luminescence in Sm.5HTRL expressing cells (solid symbols)
and a negative control cell line lacking Sm.5HTRL (open symbols). (C) Pharmacophores assayed for activity against Sm.5HTRL. Ring systems are shown with
numbering referred to throughout this manuscript. Clockwise from top - tryptamine, protoberberine, aporphine (benzylisoquinoline scaffold highlighted in bold).
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expressing Sm.5HTRL (Fig. 1A). This increase was dose-dependent
(EC50 94 ± 18 nM) and not observed in cells expressing the GloSensor
22-F reporter alone (Fig. 1B). The sensitivity and selectivity of this re-
sponse was explored for three classes of heterocyclic scaffolds – tryp-
tamine derivatives, aporphines and protoberberines. The core struc-
tures of these groups, and scaffold numbering nomenclature, are shown
in Fig. 1C.
3.1. Modifications of the tryptaminergic pharmacophore impair agonist
activity Sm.5HTRL
First, various tryptamine derivatives were selected based on their
activity at mammalian serotonergic GPCRs: the majority of which were
substituted at the terminal amine and/or the C-5 position. For example,
5-carboxamidotryptamine (5-CT) and 5-methoxytryptamine (5-MeOT)
bind to and are potent full agonists at the mammalian 5-HT7 receptors
(Bard et al., 1993; Shen et al., 1993) that are orthologous to Sm.5HTRL
(Patocka et al., 2014; Chan et al., 2016c). N-methylserotonin, methy-
lated at the terminal nitrogen, is also a full agonist at mammalian 5-
HT7 receptors (Powell et al., 2008).
In the Sm.5HTRL activity assay, the terminal amine of 5-HT ac-
commodated the addition of methyl groups: both N-methylserotonin
(N-MS) and bufotenine (5-OH-DMT) elevated cAMP with an Emax of
113 ± 28% and 99 ± 34% relative to 5-HT, respectively (Fig. 2A).
However, while the single methyl substitution on N-MS had little effect
on potency (EC50 154 ± 11 nM, compared to 94 ± 18 nM for 5-HT),
the dimethyl substitution on 5-OH-DMT decreased potency by an order
of magnitude (EC50 2.4 ± 0.2 μM). α-methylserotonin (αMS), methy-
lated at the α position of the ethylamine side chain, was a low potency,
partial agonist (Emax of 59 ± 2% relative to 5-HT; Fig. 2A).
In contrast, the 5-OH group present on serotonin was poorly tolerant
to modification. Tryptamine (‘T’, Fig. 2B), which is unsubstituted at the
C-5 position, displayed negligible activity at Sm.5HTRL. Substitutions at
the C-5 position with amide or methoxy groups to produce 5-carbox-
amidotryptamine (5-CT) and 5-methoxytryptamine (5-MeOT) respec-
tively, were poorly tolerated. Both compounds were inactive at
Sm.5HTRL (Fig. 2B). Smaller C-5 substitutions, as seen in 5-methyl-
tryptamine (5-MT) or 5-bromotryptamine (5-BrT), were better tolerated
as these compounds displayed partial agonist activity (Fig. 2B). All
compounds tested harboring dual substitutions at both the C-5 and
terminal amine positions compared with 5-HT were inactive at
Sm.5HTRL. These analogs included the psychedelic tryptamine deriva-
tives N,N-diallyl-5-methoxy tryptamine (5-MeO-DALT), 5-methoxy-
N,N-dimethyltryptamine (5-MeO-DMT), N-methyltryptamine (N-MT)
and N,N-dimethyltryptamine (DMT, Fig. 2C). None of the compounds
identified as Sm.5HTRL agonists displayed activity against HEK-
293 cells expressing the GloSensor-22F reporter alone (Supplemental
Fig. 1).
3.2. Functional characteristics of the aporphine alkaloid scaffold at
Sm.5HTRL
The aporphine alkaloids are tetracyclic benzylisoquinolines that
exhibit a range of activities at mammalian bioaminergic GPCRs
(Cabedo et al., 2009; Harding, 2016). Numerous naturally occurring
(Indra et al., 2002; Farrell et al., 2016) and synthetic (Linnanen et al.,
2001; Chaudhary et al., 2009, 2011; Kapadia and Harding, 2015)
aporphines are potent antagonists of mammalian serotonergic re-
ceptors, and preliminary structure-activity profiling of this chemical
series has been performed on Sm.5HTRL (Chan et al., 2016a). Based on
these data, we expanded our study to encompass 89 aporphine struc-
tures.
Compounds containing the aporphine core ring structure were cu-
rated from the NCI and TimTec natural product libraries (Supplemental
Table 1) and screened at an initial concentration of 10 μM. None of the
tested aporphines showed agonist activity. Full concentration-
inhibition curves were generated from hits that blocked 5-HT evoked
cAMP generation, as well as related analogs with substitutions to pro-
vide insight into structure-activity relationships at Sm.5HTRL. In total,
concentration-response curves were generated for 83 aporphines, and
this compound series demonstrated a gradation of inhibitory potencies
at Sm.5HTRL (Fig. 3A). A subset of 9 ligands (Fig. 3A) were identified
with an IC50≤ 500 nM (inhibition of 500 nM 5-HT, a maximal con-
centration) and calculated affinity, pKi≥7.0, estimated using the
Cheng-Prusoff equation. Another 20 aporphines displayed pKi values
between 6.9 and 6.0 (IC50 < 5.5 μM, Fig. 3A).
Potent compounds clustered in several chemical series (Fig. 3A,
inset). These analogs typically possessed methoxy modifications on
aporphine rings A (C-1, C-2 or C-3 position) or D (C-9 and/or C-10
position) - either as “open” (as seen with nuciferine, compound 4b) or
“closed” dioxolane ring groupings (as seen with nantenine. Compound
2a). Other substitutions were identified that were poorly tolerated.
These included, (i) addition of bulky substituents to the aporphine ni-
trogen on ring B (Fig. 3B), (ii) unsaturation of the ring C, C-6a – C-7
bond: D-glaucine and L-nuciferine were antagonists with respective
pKis of 6.8 and 7.1, but dehydroglaucine and dehydronuciferine were
both inactive (Fig. 3C) and (iii) substitution of the C-3 position on ring
A (Fig. 3D).
3.3. Functional characteristics of the protoberberine scaffold at Sm.5HTRL
Protoberberines are another class of tetracyclic benzylisoquinolines
that display antagonism at Sm.5HTRL. Rotundine is a constituent of
traditional Chinese herbal medicine preparations, with activity against
both cestodes (Das et al., 2009; Gogoi and Yadav, 2017) and schisto-
somes (Chan et al., 2016c). We previously identified racemic D/L-ro-
tundine) as an antagonist at Sm.5HTRL and showed this compound
inhibited movement of adult worms (Chan et al., 2016c). Given these
observations, we explored the structure-activity profile of proto-
berberines against Sm.5HTRL in greater detail, screening 28 molecules
(Supplemental Table 1), with a focus on structures sharing a high de-
gree of similarity with rotundine (Fig. 4A).
Racemic D/L-rotundine was a potent antagonist at Sm.5HTRL (pKi
7.2). This activity was due to the L-rotundine enantiomer, as D-ro-
tundine was inactive (Fig. 4B&C). Palmatine, which resembles ro-
tundine but contains a quaternary amine (Fig. 4A), was also inactive
(Fig. 4B&C). Closure of ring substituent methoxy groups into dioxolane
rings also resulted in a loss of activity, as observed comparing rotundine
to canadine or tetrahydrocoptisine. Shifting the placement of the D-ring
methoxy groups (rotundine verses xylopinine) also decreased potency
at Sm.5HTRL. Several compounds screened possessed an open proto-
berberine C-ring, retaining the benzylisoquinoline core (laudanosine,
papaverine, papaveraldine). None of these showed any inhibition at
Sm.5HTRL (Supplemental Table 1). Again, none of the benzylisoqui-
noline compounds that inhibited 5-HT evoked luminescence in
Sm.5HTRL expressing cells blocked forskolin-evoked signals, indicating
that drug action was not due to toxicity or other mechanisms inhibiting
cAMP generation (Supplemental Fig. 1).
3.4. Sm.5HTRL ligands alter the mobility of adult schistosomes cultured ex
vivo
Sm.5HTRL is required for worm movement (Patocka et al., 2014)
and Sm.5HTRL ligands can stimulate or block movement in larval
schistosomules and adult worms (Chan et al., 2016a, 2016c). Therefore,
we examined the effects of several substituted tryptamines (Sm.5HTRL
agonists) and benzylisoquinolines (Sm.5HTRL antagonists) against
adult schistosomes to assess whether these hits were active and whether
they recapitulated structure-activity profiles observed against
Sm.5HTRL in vitro.
Tryptaminergic Sm.5HTRL agonists stimulated worm movement,
although with decreased potency relative to results from in vitro cAMP
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assays (Fig. 5A). Consistent with assays on Sm.5HTRL, substitution of
the terminal amine was tolerated. N-methylserotonin (N-MS) was a full
agonist increasing movement by 252 ± 9%, comparable to the 5-HT
evoked-increase of 224 ± 17%. The indole C-5 position was amenable
to slight modifications. 5-methyltryptamine (5-MT) stimulated move-
ment, but only at high concentrations in the hundreds of micromolar. 5-
methoxytryptamine (5-MeOT) stimulated movement, which contrasts
with a lack of agonist activity at Sm.5HTRL in vitro (Figs. 5A and 2B). 5-
Carboxamidotryptamine (5-CT) did not stimulate movement, consistent
with this compound being inactive at Sm.5HTRL. DMT, which is mod-
ified at both the indole C-5 and terminal amine, also had no effect on
worm movement, mirroring the observed lack of activity at Sm.5HTRL.
Next, the aporphine and protoberberine Sm.5HTRL antagonists were
tested on live worms to assess whether these compounds inhibited 5-HT
evoked movement. Worms were incubated in compound for 1 h, after
which a maximal dose of serotonin (200 μM) was added to stimulate
motility. Several aporphines resembling nuciferine were studied.
Nuciferine was the most potent antagonist of worm movement, in-
hibiting 5-HT evoked movement at concentrations as low as 100 nM
(Fig. 5B). Compound phar025462, a nuciferine derivative with a
charged nitrogen and a closed dioxolane ring in place of methoxy
groups, and compound 785177, which substitutes the nuciferine A-1
methoxy with an hydroxy group, both inhibited 5-HT evoked move-
ment, albeit with lower potency in the 1–10 μM range (Fig. 5B). The
compound MDO-NPA, which potently inhibited Sm.5HTRL (pKi= 7.0),
was relatively inactive on adult worms with inhibition of 5-HT not
Fig. 2. Structure-activity relationship of tryptamine derivatives at Sm.5HTRL. (A) Action of tryptamine analogs with modifications to the ethylamine group
highlighted on the inset structure of serotonin (5-HT). N-MS = N-methylserotonin, 5-HO-DMT=bufotenine, αMS= α-methylserotonin. (B) Effect of analogs with
modifications to the highlighted tryptamine C-5 position of 5-HT (5-MT=5-methyltryptamine, 5-BrT=5-bromotryptamine, 5-MeOT=5-methoxytryptamine,
T= tryptamine, 5-CT=5-carboxamidotryptamine), or (C) both the C-5 and terminal amine groups (5-MeO DALT=N,N-diallyl-5-methoxytryptamine, 5-MeO
DMT=5-methoxy-N,N-dimethyltryptamine, DMT=N,N-Dimethyltryptamine, N-MT = N-Methyltryptamine). Values expressed relative to the maximal 5-HT re-
sponse (scaled to 100% on all Y-axes).
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surpassing 50% even at 10 μM (Fig. 5B).
Of the protoberberines, the Sm.5HTRL antagonist L-rotundine, the
inactive analog D-rotundine and the closely related palmatine were
screened on live worms. As expected, L-rotundine inhibited 5-HT
evoked movement at concentrations ≥1 μM, while D-rotundine and
palmatine showed no inhibition of 5-HT evoked movement at con-
centrations as high as 50 μM (Fig. 5C).
4. Discussion
These data highlight the structure-activity profile of tryptamine-
and benzylisoquinoline-based analogs on a schistosome 5-HT receptor
(Sm.5HTRL) that controls worm movement. 5-HT has long been re-
cognized as an important regulator of schistosome neuromusculature
(Hillman et al., 1974; Tomosky et al., 1974; Patocka et al., 2014), and
5-HT receptors have been advanced as appealing targets for anthel-
mintic drug development (Mansour, 1979, 1984; Geary et al., 1992).
The successful functional expression and miniaturization of a
Sm.5HTRL profiling assay has enabled high-throughput compound
screens to identify ligands with potential anti-schistosomal activity
(Chan et al., 2018). Given these data validating Sm.5HTRL as a viable
anti-schistosomal drug target, and the precedent of both tryptaminergic
and benzylisoquinoline natural products as serotonergic ligands
(Cabedo et al., 2009; Nichols, 2012; Harding, 2016) and antiparasitic
compounds (Bonne, 1919; Iwasa et al., 1999; Nkwengoua et al., 2009;
Das et al., 2009; Shahinas et al., 2012; Gogoi and Yadav, 2017), we
performed a more detailed exploration of the properties of these
pharmacophores that determine their efficacy as Sm.5HTRL ligands and
activity against ex vivo cultured parasites.
4.1. Tryptaminergic ligand SAR at Sm.5HTRL
Substituted tryptamines with modifications to the C-5 and terminal
amine often display agonist activity against mammalian serotonergic
receptors (Plassat et al., 1993; Shen et al., 1993; Shulgin, 1997; Powell
et al., 2008; Nichols, 2012). Compounds with subtle modifications to
the terminal amine retained agonist activity at Sm.5HTRL (Fig. 2A), but
the pharmacophore was poorly tolerant to substitution at the C-5 po-
sition (Fig. 2B). The poor activity of 5-CT and 5-MeOT at Sm.5HTRL
contrasts with the action of these ligands as full agonists at the ortho-
logous human 5-HT7 receptor (Plassat et al., 1993). Given that the
amino acid sequence of Sm.5HTRL shares just 40% similarity with the
human ortholog, it is not surprising that the two GPCRs exhibit unique
pharmacological sensitivities. A possible reason for the inactivity of the
Fig. 3. Structure-activity relationship of aporphine alkaloids at Sm.5HTRL. (A) Affinity of 84 aporphines screened against Sm.5HTRL, with pKi estimated using
the Cheng-Prusoff equation. Inset - tree resulting from hierarchical clustering of structures, with most potent hits (pKi > 7.0) denoted with black symbols, and hits
with pKi between 6.0 and 6.9 denoted with gray circles. Bottom – structures of the nine most potent compounds. (B) Structure activity profile of a nantenine-like
aporphine series with modifications to the basic B-6 nitrogen. (C) Effect of dehydrogenation of the C-6a/C-7 bond of either D-glaucine or L-nuciferine. (D) Effect of
various modifications to the D-glaucine A4 position resulting in a loss of activity at Sm.5HTRL.
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C-5 substituted tryptamines at Sm.5HTRL is that mutation of the glu-
tamic acid at the 7.35 position of the human 5-HT7 receptor abrogates
5-CT binding and function (Impellizzeri et al., 2015). This site varies in
the schistosome receptors (phenylalanine), as well as the invertebrate
C. elegans SER-7 receptor (aspartic acid) which is also refractory to 5-CT
(Hobson et al., 2006). This difference, as well as the finding that neither
DMT or related derivatives were active on Sm.5HTRL (Fig. 2C), despite
their activity on mammalian serotonergic receptors (Shen et al., 1993;
Keiser et al., 2009; Ray, 2010; Cozzi and Daley, 2016), advances our
pharmacological understanding of the unique pharmacological sig-
natures of host and parasite receptors. Other examples include the ergot
alkaloid ergotamine, a potent antagonist at the human 5-HT7 receptor
(Wacker et al., 2013) but full agonist at Sm.5HTRL (Chan et al., 2018),
as well as the commonly used 5-HT7 chemical probe SB-269970, which
is inactive at Sm.5HTRL (Chan et al., 2016c). These data emphasize the
need for considerable caution when using pharmacological probes de-
veloped against mammalian targets to study invertebrate GPCRs, while
revealing opportunities for developing parasite-selective ligands.
4.2. Determinants of benzylisoquinoline antagonism of schistosome
serotonin receptors
Our previous work identified the benzylisoquinolines rotundine
(Chan et al., 2016c) and nuciferine (Chan et al., 2016a) as potent
antagonists at Sm.5HTRL and inhibitors of schistosome movement
prompting exploration of compounds containing these ring systems in
further detail. A thorough analysis of 117 benzylisoquinoline structures
identified only antagonist hits. The strictly antagonist profile associated
with this scaffold (Figs. 3 and 4) contrasts with the agonist/partial
agonist profile of the tested tryptamine derivatives (Fig. 2) and the
mixed agonist/antagonist profile of ergot alkaloids reported elsewhere
(Chan et al., 2018).
Of the aporphine compounds tested, the most potent antagonists
had a 1,2,9,10- substituted pattern, with methoxy groups or a dioxolane
ring attached to the A and D rings of the aporphine core (nantenine,
boldine, D-glaucine). The stereochemistry of the B6-B6a bond did not
seem crucial –the levo structure L-nuciferine and dextro structures D-
glaucine, boldine and nantenine were all potent antagonists (Fig. 3).
However, saturation of the C ring at this position was important; de-
hydrogenation of the C-6a – C-7 bond of either D-glaucine or L-nuci-
ferine resulted in a loss of activity (Fig. 3C). In addition to nuciferine,
boldine and D-glaucine, which were previously identified as Sm.5HTRL
antagonists (Chan et al., 2016a), we have shown that nantenine and
ocoteine-like aporphines are also potent Sm5HTRL antagonists (pKi >
7.0, Fig. 3).
The protoberberine skeleton is similar to the aporphine skeleton –
both share a benzylisoquinoline core. Consequently, it is unsurprising
that like the aporphines, all active protoberberine compounds were
Fig. 4. Structure-activity relationship of proto-
berberine alkaloids at Sm.5HTRL. (A) Structures of
various protoberberines with structural similarity to
the Sm.5HTRL antagonist D/L-rotundine. (B) Affinity
of protoberberine ligands at Sm.5HTRL, pKi esti-
mated using the Cheng-Prusoff equation (structures
and pKi for all protoberberines screened are listed in
Supplemental Table 1). (C) Concentration response
curves for rotundine (racemate= solid blue symbol,
L-enantiomer= solid red symbol, D-en-
antiomer= solid black symbol) and related com-
pounds (symbols pair with structures shown in A.).
(For interpretation of the references to color in this
figure legend, the reader is referred to the Web ver-
sion of this article.)
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antagonists. However, unlike the aporphines, the chirality of the ste-
reocenter adjacent to the nitrogen atom seems crucial. For the an-
tagonist D/L-rotundine, the L-rotundine enantiomer was active and D-
rotundine displayed no activity at Sm.5HTRL (Fig. 4). This stereo-
chemistry mirrors rotundine's antagonism of mammalian bioaminergic
GPCRs, where L-rotundine is the active enantiomer antagonizing
mammalian dopamine D1 (Mantsch et al., 2007) and serotonin 5HT1A
receptors (Mi et al., 2017). Like the active aporphines, L-rotundine
possesses methoxy groups on the A and D rings. However, in the case of
the protoberberines, formation of dioxolane rings - closing the methoxy
positions on the A ring to produce canadine, or both the A and D rings
to produce tetrahydrocopsitine - resulted in inactive compounds. The
structure of xylopinine is identical to rotundine except for the move-
ment of one methoxy from the D9 to the D11 position, but xylopinine
was ∼10 times less potent that rotundine, indicating that the stereo-
chemistry of the methoxy groups are critical. This again differs from the
aporphines, which accommodated various methoxy group placement
around the A and D rings.
4.3. Correlation of Sm.5HTRL pharmacology with worm movement ex vivo
Schistosome movement is regulated by serotonergic signaling
through Sm.5HTRL (Patocka et al., 2014), and there is a correlation
between drug activity at this receptor and movement of parasites cul-
tured ex vivo, with Sm.5HTRL agonists stimulating movement and
Sm.5HTRL antagonists inhibiting movement (Chan et al., 2016a, 2016c,
2018). Trypaminergic ligands were agonists at Sm.5HTRL, and sub-
stitutions that eliminated activity at Sm.5HTRL also eliminated the
ability of the same compounds to stimulate worm movement (5-CT and
DMT, Fig. 2B&C and Fig. 5A). Similarly, substitutions that were toler-
ated in Sm.5HTRL cAMP assays were also generally tolerated in
movement assays. For example, N-MS (differing from 5-HT by addition
of a methyl group to the terminal amine) mirrored 5-HT in both assays.
Modification of the tryptamine C-5 position resulted in compounds that
were displayed impaired activity relative to 5-HT. Several compounds
stimulated movement of worms ex vivo, but were inactive against
Sm.5HTRL. For example, 5-MeOT did not potently activate Sm.5HTRL
(Fig. 2B), but potently stimulated movement in adult worms (Fig. 5A).
While these differences may reflect differences between Sm.5HTRL
function in live worms versus a mammalian expression system, an al-
ternative interpretation is that 5-MeOT stimulates movement through
other serotonin/bioaminergic GPCRs (Zamanian et al., 2011). This ex-
planation can be tested as other schistosome GPCRs become amenable
to functional profiling.
Reciprocally some compounds that are active against Sm.5HTRL
show poor efficacy in ex vivo worm movement assays, perhaps due to
pharmacokinetic variables such as whether the ligand is free to diffuse
through the parasite tegument, is a substrate for active transporters
such as SERT (Patocka and Ribeiro, 2007), or is degraded by worm
enzymes such as monoamine oxidase (Nimmo-Smith and Raison, 1968).
These variables may account for the right shifted dose response curves
of serotonin in cell based cAMP assays (Fig. 1A) relative to worm
movement assays (Fig. 5A). Similarly, benzylisoquinoline Sm.5HTRL
antagonists were less potent on worms (Fig. 5B&C) than in cell-based
cAMP assays (Figs. 3 and 4).
Human and parasite bioaminergic GPCRs are proven druggable
targets (Evans and Gee, 1980; Hauser et al., 2017), and exploration of
bioaminergic targets is a promising route for novel anti-schistosomal
drug development (Wang et al., 2017; Camicia et al., 2018; Chan et al.,
2018; Hahnel et al., 2018). One barrier to this work has been the
functional expression of schistosome GPCRs in scalable assays that
permit their thorough pharmacological characterization. While part of
this difficulty may stem from the divergence of schistosome GPCRs
relative to established model organisms (Sm.5HTRL has a 25% and 24%
amino acid identity to human 5-HTR7 and C. elegans SER-7, respec-
tively), this lack of conservation may also offer the opportunity to
achieving a degree of pharmacological selectivity. This is supported by
the structure-activity profiles outlined here, which highlight specific
modifications that confer affinity as well as selectivity between worm
and human orthologs. Expanding this approach to other schistosome
GPCRs and other bioactive pharmacophores will be informative for




Fig. 5. Efficacy of tryptamine and benzylisoquinoline ligands on adult S.
mansoni cultured ex vivo. (A) Quantified changes in movement of adult
parasites exposed to escalating doses of 5-HT (black, bold) and various other
substituted tryptamine derivatives. Right – structure of serotonin, with high-
lighted regions corresponding to substituted regions at the C-5 position (red; 5-
MeOT, 5-MT, 5-BrT, 5-CT), or the terminal amine (blue, N-MS). (B) Effect of
various concentrations of nuciferine-like aporphines on 5-HT evoked move-
ment. Right – structure of nuciferine, with highlighted regions corresponding to
substituted regions at the 1,2 positions of the A ring (red, compound 785177
and phar025462) and methyl group on the B ring (blue, MDO-NPA). (C) Effect
of various concentrations of protoberberines on 5-HT evoked movement. Right
– structure of L-rotundine, with highlighted regions corresponding to the ste-
reocenter in the protoberberine core and C-ring substitutions on D-rotundine
and palmatine. SMILES for all compounds are provided in Supplementary
Table 1. (For interpretation of the references to color in this figure legend, the
reader is referred to the Web version of this article.)
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